|
1
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China. CA
Cancer J Clin. 66:115–132. 2015. View Article : Google Scholar
|
|
5
|
Wang S, Zhai Y, Pang X, Niu T, Ding YH,
Dong MQ, Hsu VW, Sun Z and Sun F: Structural characterization of
coatomer in its cytosolic state. Protein Cell. 7:586–600. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hara-Kuge S, Kuge O, Orci L, Amherdt M,
Ravazzola M, Wieland FT and Rothman JE: En Bloc incorporation of
coatomer subunits during the assembly of COP-coated vesicles. J
Cell Biol. 124:883–892. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuge O, Hara-Kuge S, Orci L, Ravazzola M,
Amherdt M, Tanigawa G, Wieland FT and Rothman JE: zeta-COP, a
subunit of coatomer, is required for COP-coated vesicle assembly. J
Cell Biol. 123:1727–1734. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Orcl L, Palmer DJ, Amherdt M and Rothman
JE: Coated vesicle assembly in the Golgi requires only coatomer and
ARF proteins from the cytosol. Nature. 364:732–734. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Presley JF, Ward TH, Pfeifer AC, Siggia
ED, Phair RD and Lippincott-Schwartz J: Dissection of COPI and Arf1
dynamics in vivo and role in Golgi membrane transport. Nature.
417:187–193. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beck R, Rawet M, Wieland FT and Cassel D:
The COPI system: Molecular mechanisms and function. FEBS Lett.
583:2701–2709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee MC, Miller EA, Goldberg J, Orci L and
Schekman R: Bi-directional protein transport between the ER and
Golgi. Annu Rev Cell Dev Biol. 20:87–123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruokun C, Yake X, Fengdong Y, Xinting W,
Laijun S and Xianzhi L: Lentivirus-mediated silencing of HSDL2
suppresses cell proliferation in human gliomas. Tumour Biol.
37:15065–15077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang D, Sun SQ, Yu YH, Wu WZ, Yang SL and
Tan JM: Suppression of SCIN inhibits human prostate cancer cell
proliferation and induces G0/G1 phase arrest. Int J Oncol.
44:161–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bie CQ, Liu XY, Cao MR, Huang QY, Tang HJ,
Wang M, Cao GL, Yi TZ, Wu SL, Xu WJ and Tang SH:
Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1
receptor inhibits the growth and invasion of hepatocellular
carcinoma via down-regulating midkine expression. Oncotarget.
7:79305–79318. 2016.PubMed/NCBI
|
|
15
|
Tomuleasa C, Soritau O, Fischer-Fodor E,
Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M,
Irimie A and Kacso G: Arsenic trioxide plus cisplatin/interferon
α-2b/doxorubicin/capecitabine combination chemotherapy for
unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell
Ther. 4:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soritau O, Tomuleasa C, Aldea M, Petrushev
B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, et al:
Metformin plus temozolomide-based chemotherapy as adjuvant
treatment for WHO grade III and IV malignant gliomas. J BUON.
16:282–289. 2011.PubMed/NCBI
|
|
17
|
Buck EA, Haley JD, Thomson S, Mulvihill
MJ, Epstein DM and Miglarese MR: Combination anti-cancer therapy WO
patent application 2013152252. October 10–2013
|
|
18
|
Zhang Z, Wang T, Liu Z, Tang S, Yue M,
Feng S, Hu M, Xuan L and Chen Y: Small interfering RNA targeting of
the survivin gene inhibits human tumor cell growth in vitro. Exp
Ther Med. 14:35–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y and Huang S: Discuss the strengths
and weaknesses between tumour biotherapy and chemoradiotherapy. Med
Infor. 24:3503–3504. 2011.
|
|
20
|
Arora N, Gupta A and Singh PP: Biological
agents in gastrointestinal cancers: Adverse effects and their
management. J Gastrointest Oncol. 8:485–498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sudo H, Tsuji AB, Sugyo A, Kohda M, Sogawa
C, Yoshida C, Harada YN, Hino O and Saga T: Knockdown of COPA,
identified by loss of function screen, induces apoptosis and
suppresses tumor growth in mesothelioma mouse model. Genomics.
95:210–216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stenbeck G, Harter C, Brecht A, Herrmann
D, Lottspeich F, Orci L and Wieland FT: beta'-COP, a novel subunit
of coatomer. EMBO J. 12:2841–2855. 1993.PubMed/NCBI
|
|
23
|
Mi Y, Yu M, Zhang L, Sun C, Wei B, Ding W,
Zhu Y, Tang J, Xia G and Zhu L: COPB2 is upregulated in prostate
cancer and regulates PC-3 cell proliferation, cell cycle, and
apoptosis. Arch Med Res. 47:411–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
